Niels Boone
YOU?
Author Swipe
View article: Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more
Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more Open
Aims We aim to evaluate the clinical pharmacokinetics of a single dose interleukin‐6 (IL‐6) antibody tocilizumab (TCZ) in methylprednisolone (MP)‐treated COVID‐19 patients with cytokine storm syndrome (CSS). Methods MP pre‐treated patients…
View article: Acknowledgement to Referees
Acknowledgement to Referees Open
View article: How to select a best-value biological medicine? A practical model to support hospital pharmacists
How to select a best-value biological medicine? A practical model to support hospital pharmacists Open
Purpose With the growing availability of biosimilars on the global market, clinicians and pharmacists have multiple off-patent biological products to choose from. Besides the competitiveness of the product’s price, other criteria should be…
View article: Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method
Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method Open
Direct acting anticoagulant drugs [DOACs], consisting of apixaban, dabigatran, edoxaban and rivaroxaban have been available for various indications for 3year [edoxaban] up to over a decade [dabigatran and rivaroxaban]. These medicines have…
View article: Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method
Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method Open
Direct acting anticoagulant drugs [DOACs], consisting of apixaban, dabigatran, edoxaban and rivaroxaban have been available for various indications for 3year [edoxaban] up to over a decade [dabigatran and rivaroxaban]. These medicines have…
View article: Acknowledgement to Referees
Acknowledgement to Referees Open
View article: Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice Open
Objective To test the longitudinal association between patient-reported outcome, Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate (DAS28-ESR) i…
View article: Commutability of proficiency testing material containing amitriptyline and nortriptyline: A study within the framework of the Dutch Calibration 2.000 project
Commutability of proficiency testing material containing amitriptyline and nortriptyline: A study within the framework of the Dutch Calibration 2.000 project Open
View article: Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time Open
Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. Meth…
View article: AB0279 Rapid3 is not longitudinally associated with das28-esr in patients with rheumatoid arthritis
AB0279 Rapid3 is not longitudinally associated with das28-esr in patients with rheumatoid arthritis Open
View article: SAT0104 Treatment with methotrexate in rheumatoid arthritis patients on stable biological treatment gives better outcomes over time
SAT0104 Treatment with methotrexate in rheumatoid arthritis patients on stable biological treatment gives better outcomes over time Open
View article: Non-specific treatment effects and the patient perception of costly drug therapy
Non-specific treatment effects and the patient perception of costly drug therapy Open
View article: Editorial: nocebo effect and switching to biosimilars
Editorial: nocebo effect and switching to biosimilars Open
Linked content This article is linked to Schmitz et al paper. To view this article visit https://doi.org/10.1111/apt.14453 .
View article: The nocebo effect challenges the non-medical infliximab switch in practice
The nocebo effect challenges the non-medical infliximab switch in practice Open
View article: Transition Study of Biosimilar Infliximab in Patients with Inflammatory Bowel Disease
Transition Study of Biosimilar Infliximab in Patients with Inflammatory Bowel Disease Open
View article: Commutability of proficiency testing material containing tobramycin: a study within the framework of the Dutch Calibration 2.000 project
Commutability of proficiency testing material containing tobramycin: a study within the framework of the Dutch Calibration 2.000 project Open
Background: Results from external quality assessment schemes (EQASs) can provide information about accuracy and comparability of different measurement methods, provided that the material used in these schemes behave identical to patient sa…
View article: Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs) Open